课题基金 / 基金详情

Development of human 12/15-lipoxygenase therapeutics for stroke

Development of human 12/15-lipoxygenase therapeutics for stroke
开发人类 12/15-脂氧合酶治疗中风的药物
批准号:
9898504
负责人:
KLAUS VAN LEYEN
金额:
$66.96万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-05-01 至 2023-04-30

项目摘要

项目成果

KLAUS VAN LEYEN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Summary The goal is to develop novel therapeutics effective in stroke. This will be achieved by advancing candidate molecules toward clinical application utilizing our assay cascade to identify novel, selective inhibitors of the 12/15 lipoxygenase that protect against ischemic stroke. Our drug discovery approach will be to synthesize novel ligands based on the ML351 scaffold that are potent inhibitors of the human 12/15 lipoxygenase and that protect neurons against oxidative stress-related cell death. Candidate molecules will undergo profiling to assess criteria specifically related to the physicochemical properties of compounds in a therapeutic setting, including enzyme selectivity and tests to determine potential interactions with key metabolic enzyme systems. Best candidates will be evaluated in a battery of tests for protection against experimental stroke in mice and rabbits.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Novel Neuroprotectant to Reduce Ischemic Injury
  • 批准号:
    10576568
  • 项目类别:
  • 资助金额:
    $40.84万
  • 财政年份:
    2023
  • 负责人:
    KLAUS VAN LEYEN
  • 依托单位:
Testing the Lipoxygenase Inhibitor BPN-27332 as Acute Phase Stroke Treatment in the SPAN Network
  • 批准号:
    10671991
  • 项目类别:
  • 资助金额:
    $33.85万
  • 财政年份:
    2023
  • 负责人:
    KLAUS VAN LEYEN
  • 依托单位:
Development of human 12/15-lipoxygenase therapeutics for stroke
  • 批准号:
    9922389
  • 项目类别:
  • 资助金额:
    $66.15万
  • 财政年份:
    2018
  • 负责人:
    KLAUS VAN LEYEN
  • 依托单位:
Novel 12/15 lipoxygenase inhibitors for the treatment of stroke
  • 批准号:
    8684486
  • 项目类别:
  • 资助金额:
    $30.26万
  • 财政年份:
    2014
  • 负责人:
    KLAUS VAN LEYEN
  • 依托单位:
海外基金